The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
The Outsourcing Facilities Association (OFA) fundamentally disagrees with the FDA’s determination that the Tirzepatide injection product shortage is resolved. The fact of the matter is that ...